UPITTi004-B

CN090 C1B5B5

General

Cell Line

hPSCreg name UPITTi004-B
Cite as:
UPITTi004-B (RRID:CVCL_D0P7)
Alternative name(s)
CN090 C1B5B5
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
UPITTi004-A
(CN090 C5A5J2)
Donor diseases:
Sickle cell anemia
IGIBi001-A
(SCP28)
Donor diseases:
Sickle cell anemia
ZZUi030-A
(ZZU-iPS-SPG7-001)
Donor diseases:
Spastic paraplegia type 7
UTSWi001-A
(FA1)
Donor diseases:
Friedreich Ataxia
LUMCi002-A
(113-6, LUMC0113iATAX06)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi002-B
(113-7, LUMC0113iATAX07)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi002-C
(113-8, LUMC0113iATAX08)
Donor diseases:
Spinocerebellar Ataxia Type 1
UNIZARi001-A
(FiPSTK2-2)
Donor's gene variants:
TK2, TK2
Donor diseases:
Mitochondrial DNA depletion syndrome, myopathic form
HDZi003-A
(hiPSC NP0038)
Donor's gene variants:
TMEM43
Donor diseases:
arrhythmogenic right ventricular dysplasia 5
FRIMOi004-A
(STGD2_ FiPS4F1.7)
Donor diseases:
Stargardt Disease
HIHDNDi001-A
(A30P-3, SNCA3, Tue_020_A)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
HIHDNDi001-B
(A30P-4, SNCA4, Tue_020_B)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
ZZUi026-A
(ZZU-iPS-SCA3-003)
Donor diseases:
Spinocerebellar Ataxia Type 3
BGUi001-A
(BGU01iPORhet)
Donor diseases:
P450 Oxidoreductase Deficiency
BGUi002-A
(BGU02iPOR)
Donor diseases:
P450 Oxidoreductase Deficiency
BGUi003-A
(BGU03iPOR)
Donor diseases:
P450 Oxidoreductase Deficiency
AIBNi015-A
(SPG1-AU01C15)
Donor diseases:
hereditary spastic paraplegia 56
UKBi014-A
(A-257s2)
Donor diseases:
Walker-Warburg syndrome
VUi011-A
(SCZ 3.5)
Donor diseases:
Schizophrenia
DHMi004-A
(HOS_1460)
Donor diseases:
Holt-Oram Syndrome
IDIBGIi003-A
(​RB20235)
Donor diseases:
Brugada syndrome
RMCGENi020-A
(IPS15-00004)
Donor diseases:
Stargardt Disease
RMCGENi021-A
(IPS22-00087)
Donor diseases:
Stargardt Disease
SCTCi017-A
(IPS15-00006)
Donor diseases:
Stargardt disease
SCTCi018-A
(IPS15-00007)
Donor diseases:
Stargardt disease
ZZUi017-A
(ZZU-iPS-SCA6-001)
Donor diseases:
Spinocerebellar Ataxia Type 6
TNRMCi001-A
(iTAF32)
Donor's gene variants:
CFTR
Donor diseases:
Cystic fibrosis
FRIMOi003-A
(STGD1_ FiPS4F1.5)
Donor diseases:
Stargardt Disease
LUMCi022-A
(115-1, LUMC0115iATAX01)
Donor diseases:
Spinocerebellar Ataxia Type 1
Last update 16th August 2023
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator University of Pittsburgh (UPITT)

External Databases

BioSamples SAMEA114066531
Cellosaurus CVCL_D0P7
Wikidata Q123033756

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: allowed

Donor Information

General Donor Information

Sex male
Ethnicity Black

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA114066391

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Please provide the contact information Consent was given at Children's National Hospital via Principal Investigator - Michael Hsieh, MD, PhD (mhsieh@childrensnational.org): Research Coordinator - Breanne De Vera (BDEVERA@childrensnational.org)
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? University of Pittsburgh IRB & clinicaltrials.gov
Approval number STUDY19110083 & NCT02972801
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Synonyms
  • fibroblast
  • Fibroblasts
  • Fibroblast
  • FIBROBLAST
show more synonyms

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions

Surface coating Matrigel/Geltrex
Medium mTeSR™ Plus
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
DPPA2
Yes
NANOG
Yes
SSEA-4
Yes
TRA 1-81
Yes
SOX2
Yes
POU5F1 (OCT-4)
Yes
Teratoma analysis shows a robust, non-cancerous, tri-lineage differential potential. Teratomas were processed and analysed with a histopathologist and show definitive differentiation for each germ layer (Fig. 1E). Endodermal differentiation in both lines presented a strong gastrointestinal phenotype, indicated by the presence of a lumen (L) and intestinal crypts (IC) (left). Mesoderm differentiation is indicated by cartilage (C) and bone (B) in C5A5J2 (middle, top), and by cartilage and muscle fibers (MF) in C1B5B5 (middle, bottom). Ectoderm differentiation in both lines presented with retinal pigment (RP), and in C5A5J2, a neural rosette (NR) was also observed (top, right).
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
Morphology
Paper Figure
C1B5B5 Teratoma Mouse 1.pdf
Endoderm is bottom row.
C1B5B5 Teratoma Mouse 2.pdf
Endoderm is bottom row.
C1B5B5 Teratoma Mouse 3.pdf
Endoderm is bottom row.
Protocol or reference
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
Morphology
C1B5B5 Teratoma Mouse 1.pdf
Mesoderm is middle row.
C1B5B5 Teratoma Mouse 2.pdf
Mesoderm is middle row.
C1B5B5 Teratoma Mouse 3.pdf
Mesoderm is middle row.
Protocol or reference
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma
Morphology
C1B5B5 Teratoma Mouse 1.pdf
Ectoderm is top row.
C1B5B5 Teratoma Mouse 2.pdf
Ectoderm is top row.
C1B5B5 Teratoma Mouse 3.pdf
Ectoderm is top row.
Protocol or reference

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes

Other Genotyping (Cell Line)